Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 1

Status

Unknown 2Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6Observational 5

Sponsor

Conditions

Breast Neoplasms 10184Neoplasms 7810Carcinoma, Non-Small-Cell Lung 5760Prostatic Neoplasms 5024Colorectal Neoplasms 4606Lung Neoplasms 3725Leukemia, Myeloid, Acute 3102Neoplasm Metastasis 3083Multiple Myeloma 3082Pancreatic Neoplasms 2845Melanoma 2653Ovarian Neoplasms 2573Lymphoma 2571Carcinoma, Hepatocellular 2480Stomach Neoplasms 2330Recurrence 2230Head and Neck Neoplasms 2103Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2058Leukemia 2013Brain Neoplasms 1905Glioblastoma 1797Colonic Neoplasms 1791Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1720Uterine Cervical Neoplasms 1693Squamous Cell Carcinoma of Head and Neck 1654Lymphoma, Follicular 1652Lymphoma, Large B-Cell, Diffuse 1597Carcinoma, Renal Cell 1577

Interventions

Nivolumab 3Cisplatin 2Albumin-Bound Paclitaxel 2tislelizumab 1spartalizumab 1Taxes 1Standard of Care 1Radiotherapy 1Immunotherapy 1Gemcitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Muscle-Invasive Bladder Carcinoma × Clear all
NCT05295992 2026-03-06

ARTIA-Vesica

Varian, a Siemens Healthineers Company

Phase NA Active not recruiting
110 enrolled

Muscle-Invasive Bladder Carcinoma

NCT04506554 2025-07-04

A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer

Fox Chase Cancer Center

Phase 2 Active not recruiting
81 enrolled

Muscle-Invasive Bladder Carcinoma

NCT04724928 2025-01-15

EFFORT-MIBC

University Hospital, Ghent

Phase 2 Recruiting
156 enrolled

Muscle-Invasive Bladder Carcinoma

NCT05203913 2024-10-04

CNN-BC

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 2 Recruiting
32 enrolled

Muscle-Invasive Bladder Carcinoma

NCT04876313 2022-04-06

NURE-Combo

IRCCS San Raffaele

Phase 2 Unknown
29 enrolled

Muscle-Invasive Bladder Carcinoma

NCT04909775 2021-06-02

Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer

Ruijin Hospital

Phase 2 Unknown
40 enrolled

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡